Form 4: Amylyx Pharmaceuticals Director Acquires Stock Options
Insider Transaction Filing
Amylyx Pharmaceuticals reports a Form 4 filing detailing the acquisition of stock options by Director George M. Milne Jr.
Summary
- Director George M. Milne Jr. acquired 24,372 stock options on June 4, 2026.
- These options have an exercise price of $14.31 and an expiration date of June 3, 2036.
- The shares subject to the option will vest in full on the earlier of June 4, 2027, or the next annual meeting, contingent on continuous service.
- The filing indicates this transaction was made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c) affirmative defense conditions.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard insider stock option grant rather than a significant event impacting company performance or strategy.
Positives
- Director George M. Milne Jr. has acquired a significant number of stock options, indicating continued commitment and potential future value appreciation.
- The transaction is structured under a Rule 10b5-1(c) plan, suggesting a pre-determined and compliant trading strategy.
Future Outlook
The vesting schedule for the stock options suggests a medium-term outlook for the reporting person's continued engagement and potential benefit from the company's performance.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions in the pharmaceutical sector, reflecting executive and director compensation structures and alignment with shareholder interests.
Stakeholder Impact
- Shareholders: The grant of options to a director aligns their interests with shareholders, potentially incentivizing performance that could lead to share price appreciation.
Next Steps
- Continuous service by the Reporting Person through the vesting date.
- Potential exercise of stock options upon vesting.
Key Dates
| Date | Description |
|---|---|
| 06/04/2026 | Earliest transaction date and date of stock option acquisition. |
| 06/03/2036 | Expiration date of the acquired stock options. |
| 06/04/2027 | Potential full vesting date for the stock options. |
| 06/08/2026 | Date of signature for the filing. |
Keywords
Amylyx Pharmaceuticals, Form 4, Stock Options, Director, Beneficial Ownership, Rule 10b5-1(c), AML X
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.